--- title: "Olema Pharmaceuticals (OLMA) news: offering" url: "https://aibio.space/companies/olema-pharmaceuticals/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "OLMA offering news: Olema Oncology announces $250.0 million private placement and Novartis supply deal. Olema Pharmaceuticals, Inc." --- OLMA Olema Pharmaceuticals, Inc. NASDAQ · United States # Olema Pharmaceuticals (OLMA) news OLMA offering news Financings · 2024-12-02 ## [Olema Oncology announces $250.0 million private placement and Novartis supply deal](https://aibio.space/news/olema-oncology-announces-250-0-million-private-placement-novartis/) Olema is selling 19,928,875 shares at $9.08 and pre-funded warrants for 7,604,163 shares. Novartis will supply ribociclib for the planned Phase 3 OPERA-02 trial. ## Latest Olema Pharmaceuticals news We have not published a story on Olema Pharmaceuticals yet. When there is news, it will appear here. ## Olema Pharmaceuticals at a glance - **Ticker**: OLMA - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $461.1 million ### Related companies - [Spyre Therapeutics](https://aibio.space/companies/spyre-therapeutics/) NASDAQ: SYRE - [Ocular Therapeutix](https://aibio.space/companies/ocular-therapeutix/) NASDAQ: OCUL - [Vogenx](https://aibio.space/companies/vogenx/) NASDAQ: VOGX - [Amneal Pharmaceuticals](https://aibio.space/companies/amneal-pharmaceuticals/) NASDAQ: AMRX - [Corvus Pharmaceuticals](https://aibio.space/companies/corvus-pharmaceuticals/) NASDAQ: CRVS - [Quoin Pharmaceuticals](https://aibio.space/companies/quoin-pharmaceuticals/) NASDAQ: QNRX - [Alnylam Pharmaceuticals](https://aibio.space/companies/alnylam-pharmaceuticals/) NASDAQ: ALNY - [OnKure Therapeutics](https://aibio.space/companies/onkure-therapeutics/) NASDAQ: OKUR ### Also on NASDAQ - [PepGen](https://aibio.space/companies/pepgen/) PEPG - [Bon Natural Life](https://aibio.space/companies/bon-natural-life/) BON - [Bionano Genomics](https://aibio.space/companies/bionano-genomics/) BNGO - [Bluejay Diagnostics](https://aibio.space/companies/bluejay-diagnostics/) BJDX - [Modular Medical](https://aibio.space/companies/modular-medical/) MODD - [Aclaris Therapeutics](https://aibio.space/companies/aclaris-therapeutics/) ACRS ## What Olema Pharmaceuticals does Olema Pharmaceuticals is a clinical-stage biopharmaceutical company developing next-generation targeted therapies for breast cancer and beyond, with a focus on endocrine-driven cancers, nuclear receptors and mechanisms of acquired resistance. Its lead product candidate, palazestrant (formerly OP-1250), is an oral small molecule with dual activity as a complete estrogen receptor antagonist and selective estrogen receptor degrader, investigated in ER-positive, HER2-negative breast cancer. Across more than 400 patients in clinical studies, the company reports strong anti-tumor activity and favorable tolerability. The pivotal Phase 3 OPERA-01 trial tests palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer. The pivotal Phase 3 OPERA-02 trial tests palazestrant with ribociclib in front-line metastatic disease, supported by a clinical trial collaboration and supply agreement with Novartis Pharma AG. Palazestrant is also in Phase 1/2 studies combined with CDK4/6 inhibitors, alpelisib, everolimus and atirmociclib. The second clinical candidate, OP-3136, is an oral KAT6 inhibitor in a Phase 1 trial. Olema relies on third parties for manufacturing. | Product or program | What it is | Stage | |---|---|---| | palazestrant (OP-1250) | Oral dual ER antagonist and degrader for ER-positive, HER2-negative breast cancer | Phase 3 (OPERA-01 and OPERA-02) | | OP-3136 | Oral KAT6 inhibitor for breast and other solid tumors | Phase 1, enrolling patients | Summarised from the company's [10-K filed Mar 16, 2026](https://www.sec.gov/Archives/edgar/data/1750284/000119312526107169/olma-20251231.htm). ## Olema Pharmaceuticals annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$157.7 million](https://www.sec.gov/Archives/edgar/data/1750284/000119312526107169/) | [$124.5 million](https://www.sec.gov/Archives/edgar/data/1750284/000119312526107169/) | | Net income (loss) | [-$162.5 million](https://www.sec.gov/Archives/edgar/data/1750284/000119312526107169/) | [-$129.5 million](https://www.sec.gov/Archives/edgar/data/1750284/000119312526107169/) | | Cash from operations | [-$146.7 million](https://www.sec.gov/Archives/edgar/data/1750284/000119312526107169/) | [-$104.4 million](https://www.sec.gov/Archives/edgar/data/1750284/000119312526107169/) | | Cash and equivalents | [$48.3 million](https://www.sec.gov/Archives/edgar/data/1750284/000119312526342383/) | [$139.5 million](https://www.sec.gov/Archives/edgar/data/1750284/000119312526107169/) | | Short-term investments | [$457.1 million](https://www.sec.gov/Archives/edgar/data/1750284/000119312526342383/) | [$294.6 million](https://www.sec.gov/Archives/edgar/data/1750284/000119312526107169/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $48.6 million, plus short-term investments of $412.5 million, $461.1 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Olema Pharmaceuticals Has Olema Pharmaceuticals raised money recently? Our latest story on this, dated Dec 2, 2024: "Olema Oncology announces $250.0 million private placement and Novartis supply deal". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/olema-oncology-announces-250-0-million-private-placement-novartis/). What is the ticker symbol of Olema Pharmaceuticals? Olema Pharmaceuticals, Inc. trades under the ticker OLMA on NASDAQ. Where is Olema Pharmaceuticals listed? Olema Pharmaceuticals, Inc. is listed on NASDAQ. What is the SEC CIK of Olema Pharmaceuticals? The SEC Central Index Key (CIK) for Olema Pharmaceuticals, Inc. is 1750284. Its filings are on SEC EDGAR. How many shares does Olema Pharmaceuticals have outstanding? 87,497,607 shares as of 2026-08-06, per the cover page of its 10-Q filed 2026-08-10. Which country or territory is Olema Pharmaceuticals listed under? Our directory records Olema Pharmaceuticals, Inc. under United States. What does Olema Pharmaceuticals do? Our directory classifies Olema Pharmaceuticals, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Olema Pharmaceuticals? The ISIN recorded for Olema Pharmaceuticals, Inc. is US68062P1066. Does aibio.space cover Olema Pharmaceuticals? aibio.space lists Olema Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Olema Pharmaceuticals incorporated? SEC records list its state or country of incorporation as DE. What does Olema Pharmaceuticals develop? Olema Pharmaceuticals is a clinical-stage biopharmaceutical company developing next-generation targeted therapies for breast cancer and beyond, with a focus on endocrine-driven cancers, nuclear receptors and mechanisms of acquired resistance. Its lead product candidate, palazestrant (formerly OP-1250), is an oral small molecule with dual activity as a complete estrogen receptor antagonist and selective estrogen receptor degrader, investigated in ER-positive, HER2-negative breast cancer. What is palazestrant (OP-1250) from Olema Pharmaceuticals? palazestrant (OP-1250): Oral dual ER antagonist and degrader for ER-positive, HER2-negative breast cancer Stage: Phase 3 (OPERA-01 and OPERA-02). What is OP-3136 from Olema Pharmaceuticals? OP-3136: Oral KAT6 inhibitor for breast and other solid tumors Stage: Phase 1, enrolling patients. Is Olema Pharmaceuticals profitable? Olema Pharmaceuticals, Inc. reported a net loss of $162.5 million for the fiscal year ended Dec 31, 2025, and used $146.7 million of cash in operations, per its annual report to the SEC. How much does Olema Pharmaceuticals spend on research and development? $157.7 million in the fiscal year ended Dec 31, 2025, per its annual report. ## Investor discussion: Olema Pharmaceuticals Members talk about Olema Pharmaceuticals (OLMA). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Olema Pharmaceuticals, newest first. Each line links the filing it comes from. 1. 2026-08-13 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1750284/000119312526347853/olma-ex99_1.htm) 2. 2025-12-11 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3ASR. [Source](https://www.sec.gov/Archives/edgar/data/1750284/000119312525316125/d848104ds3asr.htm) 3. 2025-11-18 Financings Reported a financing. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1750284/000119312525286206/d86905d8k.htm) 4. 2025-01-06 Financings Reported an unregistered sale of its securities. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1750284/000119312525002157/d901834ds3.htm) 5. 2024-12-02 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1750284/000095017024131965/olma-ex99_1.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:OLMA on TradingView](https://www.tradingview.com/symbols/NASDAQ-OLMA/). ## SEC filings and registration - **SEC name**: Olema Pharmaceuticals, Inc. - **CIK**: 1750284 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: OLMA (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 780 BRANNAN STREET, SAN FRANCISCO, CA, 94103 - **Phone**: (415) 651-3316 - **Shares outstanding**: 87,497,607 as of 2026-08-06 (10-Q filed 2026-08-10) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1750284/000119312526423002/olma-20261012.htm) filed 2026-10-15 - [8-K](https://www.sec.gov/Archives/edgar/data/1750284/000119312526347853/olma-20260813.htm) filed 2026-08-13 - [10-Q](https://www.sec.gov/Archives/edgar/data/1750284/000119312526342383/olma-20260630.htm) filed 2026-08-10 - [8-K](https://www.sec.gov/Archives/edgar/data/1750284/000119312526342334/olma-20260810.htm) filed 2026-08-10 - [8-K](https://www.sec.gov/Archives/edgar/data/1750284/000119312526279483/olma-20260617.htm) filed 2026-06-23 - [8-K](https://www.sec.gov/Archives/edgar/data/1750284/000119312526237832/olma-20260526.htm) filed 2026-05-26 - [8-K](https://www.sec.gov/Archives/edgar/data/1750284/000119312526234848/olma-20260521.htm) filed 2026-05-21 - [10-Q](https://www.sec.gov/Archives/edgar/data/1750284/000119312526218156/olma-20260331.htm) filed 2026-05-12 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001750284), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Olema Pharmaceuticals, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker OLMA, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Olema Pharmaceuticals, Inc. - **Ticker**: OLMA - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US68062P1066 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-OLMA/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/olema-pharmaceuticals/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Olema Pharmaceuticals (OLMA) news: offering", 2026-10-31, https://aibio.space/companies/olema-pharmaceuticals/